I. Taylor

发表

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

D. Auclair, P. Vincent, G. Bollag, 2004, Cancer Research.

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.

S. Wilhelm, Lila Adnane, I. Taylor, 2006, Methods in enzymology.

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.

G. Giaccone, M. Kris, P. Jänne, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer.

L. Perkins, I. Enyedy, Antonella Bacchiocchi, 2007, Bioorganic & medicinal chemistry letters.

Receptor Tyrosine Kinases Involved in Tumor Progression Activity and Targets the RAF/MEK/ERK Pathway and BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor

D. Auclair, P. Vincent, G. Bollag, 2004 .

Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer

P. Jänne, K. O'Byrne, T. Mok, 2013 .

A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

G. Giaccone, P. Jänne, F. Khuri, 2014, Cancer.

First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers.

M. Kris, P. Jänne, S. Ou, 2012 .

Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).

M. Krzakowski, S. Ramalingam, L. Denis, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline phosphorylated ERK levels in renal cell carcinoma patients from a phase II study of BAY 43–9006.

S. Wilhelm, D. Wilkie, Angela McNabola, 2004 .

Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

J. Christensen, R. Finn, C. Britten, 2012, Molecular Cancer Therapeutics.

Preclinical Development Dacomitinib ( PF-00299804 ) , an Irreversible Pan-HER Inhibitor , Inhibits Proliferation of HER 2-Ampli fi ed Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

J. Christensen, R. Finn, C. Britten, 2012 .

Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer

J. Flanagan, C. Crews, Y. Qian, 2021, Experimental and Molecular Therapeutics.

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.

C. Paweletz, M. Kris, P. Jänne, 2014, The Lancet. Oncology.

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.

P. Jänne, K. O'Byrne, T. Mok, 2014, The Lancet. Oncology.

Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009).

P. Jänne, K. O'Byrne, T. Mok, 2014 .

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

Keunchil Park, M. Krzakowski, S. Ramalingam, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

S. Wilhelm, M. Lynch, Chen Chen, 2007, Cancer Chemotherapy and Pharmacology.

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

D. Amadori, L. Schwartz, S. Ricci, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

P. Jänne, J. Engelman, J. Schellens, 2011, Clinical Cancer Research.

Phase I/II Trial

M. Ahn, Keunchil Park, Dong-Wan Kim, 2020 .

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

P. Jänne, K. O'Byrne, T. Mok, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

P. Jänne, K. O'Byrne, T. Mok, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial

M. Ahn, Keunchil Park, Dong-Wan Kim, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dacomitinib (PF-00299804), An Irreversible Pan-Her Tyrosine Kinase Inhibitor (TKI), For First-Line Treatment of EGFR-Mutant or Her2-Mutant or -Amplified Lung Cancers

M. Kris, P. Jänne, S. Ou, 2012 .

Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer

C. Crews, T. Neklesa, I. Taylor, 2021, Experimental and Molecular Therapeutics.

First-Line Dacomitinib (PF-00299804), an Irreversible Pan-Her Tyrosine Kinase Inhibitor, for Patients with EGFR-Mutant Lung Cancers

M. Kris, P. Jänne, S. Ou, 2012 .

Abstract 432: Mechanisms of acquired resistance to ARV-471, a novel PROTAC® estrogen receptor degrader

J. Teh, I. Taylor, R. Gedrich, 2023, Cancer Research.

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

D. Auclair, P. Vincent, G. Bollag, 2004, Cancer Research.

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.

C. Paweletz, M. Kris, P. Jänne, 2014, The Lancet. Oncology.

Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial.

Kelvin K. W. Chan, S. Kamel‐Reid, L. Siu, 2013 .

Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

L. Siu, S. Chia, S. Hotte, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase III study.

T. Mok, P. Janne, V. Antić, 2012 .